KIT and systemic mastocytosis: Here we report the results of an investigator-initiated clinical trial that evaluated the efficacy of imatinib targeted therapy in 10 patients with SM −9 patients with WDSM (including 3 CM, 3 ISM and 3 MCL) and one SM-AHNMD– lacking mutations at exon 17 of the KIT gene selected from 453 consecutive patients diagnosed with SM.